Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the Company moves into its
Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense® HER2 Phase I study
Imagion Biosystems today announced “Issue of unlisted performance options under Equity Incentive Plan”. Read the announcement.
The attached “Appendix 3G: Notification of issue, conversion or payment up of equity +securities” was released to market. View Appendix 3G.
Imagion Biosystems has today advised that 2,500,000 performance rights have vested and were issued as ordinary shares to Executive Chairman and CEO, Bob Proulx today,
Imagion Biosystems gives notice that, on 4 September 2020 the Company issued 2,514,666 fully paid ordinary shares (Shares) in the Company as the result of
Imagion Biosystems announce that it has received a total of $82,939.98 for the exercise of Listed Options. Comprised of $64,189.98 for 2,139,666 Listed Options exercisable at
Imagion Biosystems gives notice that, on 27 August 2020 the Company issued 6,080,000 fully paid ordinary shares (Shares) in the Company as the result of
Imagion Biosystems announce that it has received $122k for the exercise of 4,080,000 listed options exercisable at 3 cents expiring on 28 April 2023. In
The attached ASX announcement in relation to IBX Appendix 3G was released to market. Read the announcement.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance